Eli Lilly and Company (LLY): Marketing Mix Analysis [June-2026 Updated]

This ready-made late-2025 Marketing Mix Analysis gives you a clear, research-based view of Eli Lilly and Company’s business across obesity, diabetes, oncology, and neuroscience, showing how Mounjaro, Zepbound, Kisunla, and Verzenio support its market position. You’ll see how the company reaches patients through U.S. and global commercialization, specialty pharmacies, health systems, LillyDirect, retail and mail-order channels, and how it uses heavy HCP promotion, direct-to-consumer obesity advertising, conference data launches, and premium specialty-drug pricing with rebates, copay support, and cash-pay options.

Eli Lilly and Company - Marketing Mix: Product

Eli Lilly and Company’s product mix centers on tirzepatide, donanemab, and abemaciclib. In 2023, Mounjaro and Verzenio each generated $5.1 billion in revenue.

Mounjaro is the diabetes anchor in Eli Lilly and Company’s product mix. The product uses tirzepatide, a dual GIP/GLP-1 receptor agonist, and is sold as a once-weekly injection across 6 strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. In SURPASS-2, after 40 weeks, HbA1c changed by 2.01% at 5 mg, 2.24% at 10 mg, and 2.30% at 15 mg, versus 1.86% with semaglutide 1 mg. Body weight changed by 7.6 kg, 9.3 kg, and 11.2 kg, versus 5.7 kg with semaglutide.

Zepbound is the obesity product built on the same tirzepatide platform. It is marketed for adults with BMI of 30 or more, or 27 or more with at least 1 weight-related condition. In SURMOUNT-1, mean weight loss at 72 weeks was 15.0% with 5 mg, 19.5% with 10 mg, and 20.9% with 15 mg, compared with 3.1% for placebo. The same molecule also extends into sleep apnea development, where SURMOUNT-OSA enrolled 469 adults across 2 phase 3 trials.

Kisunla is donanemab, an anti-amyloid monoclonal antibody for early symptomatic Alzheimer’s disease. The pivotal TRAILBLAZER-ALZ 2 study enrolled 1,736 participants and followed them for 76 weeks. That makes Kisunla a biologic product with a very different delivery model from the company’s weekly injectable metabolic products and oral oncology therapy.

Verzenio is abemaciclib, an oral CDK4/6 inhibitor used in HR-positive, HER2-negative breast cancer. Eli Lilly and Company reported $5.1 billion of Verzenio revenue in 2023, and the monarchE study enrolled 5,637 patients. The product matters because it gives the company a durable oncology franchise with an oral, twice-daily dosage form rather than an injectable format.

• 2 marketed tirzepatide brands: Mounjaro and Zepbound
• 6 dose strengths for each tirzepatide brand: 2.5 mg to 15 mg
• 72 weeks of pivotal weight-loss data for Zepbound in SURMOUNT-1
• 40 weeks of pivotal diabetes data for Mounjaro in SURPASS-2
• 1,736 participants in the Kisunla pivotal study
• 5,637 patients in the Verzenio monarchE study

Eli Lilly and Company - Marketing Mix: Place

2024: LillyDirect launched in 50 states and Washington, D.C.

$5.3 billion: manufacturing expansion announced for Lebanon, Indiana.

1.2 million square feet: planned size of the Lebanon, Indiana manufacturing site.

U.S. and global commercialization

• 50 states
• Washington, D.C.
• 2024

Specialty pharmacies and health systems

• Specialty pharmacies
• Health systems
• Limited-distribution medicines
• Clinic-based administration

LillyDirect direct-to-consumer access

• 2024
• 50 states
• Washington, D.C.

Retail and mail-order fulfillment

• Retail pharmacies
• Mail-order pharmacies
• Direct shipment

Expanding manufacturing footprint

• $5.3 billion
• 1.2 million square feet
• Lebanon, Indiana

Eli Lilly and Company - Marketing Mix: Promotion

2023-11-08, 2024, 2,539, 1,879, 72, 40, 15.0%, 19.5%, 20.9%, 2.01, 2.24, 2.30, $399, $549, 2.5 mg, 15 mg.

Heavy HCP field promotion is built on 2,539-patient and 1,879-patient phase 3 datasets, with 72-week and 40-week endpoints, and dose levels from 2.5 mg to 15 mg.

Direct-to-consumer obesity advertising is anchored to 2023-11-08, when Zepbound received U.S. approval, and to the dose ladder of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The clinical proof points used in that message include 15.0%, 19.5%, and 20.9% mean weight loss, versus 3.1% for placebo.

LillyDirect launched in 2024, with self-pay vial prices of $399 and $549.

Conference-driven clinical data launches use exact sample sizes and endpoints: SURMOUNT-1 at 2,539 adults over 72 weeks, and SURPASS-2 at 1,879 adults over 40 weeks. The promotion package also uses HbA1c reductions of 2.01, 2.24, and 2.30 percentage points.

Disease-awareness and support programs sit on the same numeric story: 2.5 mg starter dosing, 15 mg ceiling dosing, and $399 and $549 cash-pay access points.

• 2023-11-08
• 2024
• 2,539
• 1,879
• 72
• 40
• 15.0%
• 20.9%
• 2.01
• 2.30
• $399
• $549

Eli Lilly and Company - Marketing Mix: Price

Premium specialty-drug pricing: Zepbound list price: $1,059.87 per month. LillyDirect self-pay vial prices: $399 and $549. Difference from list price: $660.87 and $510.87. Price reduction versus list: 62.4% and 48.2%.

Net pricing shaped by rebates: Eli Lilly and Company cut U.S. insulin list prices by 70% in 2023. Humalog and Humulin insulin access under the Lilly Insulin Value Program: $35 per month.

Copay support for patients: $35 per month for Lilly insulins under the Lilly Insulin Value Program. Eli Lilly and Company patient support programs for selected medicines have used $25 as a copay floor.

Cash-pay access options: LillyDirect self-pay access points: $399 and $549. Against a $1,059.87 list price, the cash-pay gap is $660.87 and $510.87.

Value-based access pressure: Medicare Part D out-of-pocket cap: $2,000 in 2025. Monthly specialty-drug pricing above $1,000 faces payer pressure under that ceiling.

• $1,059.87
• $399
• $549
• $660.87
• $510.87
• 62.4%
• 48.2%
• 70%
• $35
• $25
• $2,000